Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.

Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP.

PLoS One. 2010 Mar 19;5(3):e9646. doi: 10.1371/journal.pone.0009646.

2.

ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.

Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS 3rd.

Mol Cell Biol. 2009 Sep;29(18):4935-48. doi: 10.1128/MCB.01705-08. Epub 2009 Jul 13.

3.

The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.

Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K, Atfi A, Earp HS 3rd.

Mol Cell Biol. 2009 Feb;29(3):892-906. doi: 10.1128/MCB.00595-08. Epub 2008 Dec 1.

4.

Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.

Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp HS 3rd.

Mol Endocrinol. 2008 Oct;22(10):2307-21. doi: 10.1210/me.2008-0055. Epub 2008 Jul 24.

5.

ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.

Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS 3rd.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):235-46. doi: 10.1007/s10911-008-9080-x. Epub 2008 Apr 25. Review.

6.

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J.

J Clin Invest. 2008 Jan;118(1):64-78.

7.

HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.

Strunk KE, Husted C, Miraglia LC, Sandahl M, Rearick WA, Hunter DM, Earp HS 3rd, Muraoka-Cook RS.

Cancer Res. 2007 Jul 15;67(14):6582-90.

8.

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation.

Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS, Dy R, Muraoka-Cook RS, Earp HS 3rd.

Mol Endocrinol. 2007 Aug;21(8):1861-76. Epub 2007 May 15.

9.

Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.

Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA Jr, McCall W, Sgagias MK, Cowan KH, Earp HS 3rd.

Mol Cell Biol. 2006 Sep;26(17):6412-24.

10.

The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells.

Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS 3rd.

Mol Biol Cell. 2006 Sep;17(9):4118-29. Epub 2006 Jul 12.

11.

Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.

Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL.

Oncogene. 2006 Jun 8;25(24):3408-23. Epub 2005 Sep 26.

PMID:
16186809
12.

Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression.

Muraoka-Cook RS, Dumont N, Arteaga CL.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s. Review.

13.

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors.

Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL.

Cancer Res. 2004 Dec 15;64(24):9002-11.

Supplemental Content

Loading ...
Support Center